HF
XENE icon

HRT Financial’s Xenon Pharmaceuticals XENE Stock Holding History

HRT Financial’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.55M Hold
129,800
– – 0.02% 754
2025
Q4 		$5.82M Buy
+129,800
New +$5.45M 0.02% 707

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HRT Financial's XENE Position: Q1 2025 in Review

HRT Financial sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 7,171 shares — an estimated $281K sold.

HRT Financial first reported a position in XENE in Q4 2019 and held it in 13 quarters. The position peaked at $3.83M in Q4 2023. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • HRT Financial reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 7,171 Xenon Pharmaceuticals shares in Q1 2025, an estimated $281K.
  • HRT Financial first reported a position in Xenon Pharmaceuticals in Q4 2019 and held it in 13 quarters.
  • HRT Financial's Xenon Pharmaceuticals position peaked at $3.83M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.